GeoVax Labs(GOVX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update GEO-MVA received favorable European regulatory guidance supporting streamlined development pathway GEO-CM04S1 demonstrates superior robust immune responses in CLL patients; data presented at EHA 2025 Gedeptin® highlighted strong safety and efficacy for the treatment of solid tumors; data presented at AACR 2025 Company to host conference call today at 4:30 p.m. ET ATLANTA, GA, July 28, 2025 – GeoVax Labs, Inc. (Nas ...